{"id":"enoxaparin-high-dose-group","safety":{"commonSideEffects":[{"rate":"1-10","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Injection site hematoma"},{"rate":"1-5","effect":"Elevated transaminases"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:27:28.786918","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The high-dose formulation is used in acute clinical settings requiring rapid and sustained anticoagulation.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:17.835Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)"},{"name":"Deep vein thrombosis and pulmonary embolism prophylaxis and treatment"},{"name":"Acute ST-elevation myocardial infarction"}]},"_fixedFields":["pubmed(5)"],"trialDetails":[{"nctId":"NCT06825416","phase":"PHASE3","title":"A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2025-03-16","conditions":"Prevention of Arterial and Venous Thrombosis","enrollment":1166},{"nctId":"NCT05752461","phase":"PHASE2","title":"SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2023-04-12","conditions":"Prevention of Venous Thromboembolism After Knee Arthroplasty","enrollment":353},{"nctId":"NCT05819125","phase":"","title":"Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin","status":"TERMINATED","sponsor":"Sanofi","startDate":"2023-04-25","conditions":"Venous Thromboembolism","enrollment":21000},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT03145675","phase":"PHASE4","title":"Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2017-05-12","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":378},{"nctId":"NCT04808882","phase":"PHASE2","title":"ANTIcoagulation in Severe COVID-19 Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-14","conditions":"Severe COVID-19 Pneumonia","enrollment":353},{"nctId":"NCT04110444","phase":"","title":"Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy","status":"WITHDRAWN","sponsor":"Fayoum University Hospital","startDate":"2017-01","conditions":"High Risk Pregnancy","enrollment":""},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT02600260","phase":"NA","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2014-12-01","conditions":"Thrombophilia Associated With Pregnancy, Perioperative/Postoperative Complications, Venous Thrombosis","enrollment":7212},{"nctId":"NCT00152971","phase":"PHASE3","title":"Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Arthroplasty, Replacement, Knee, Thromboembolism","enrollment":2615},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00917254","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":369},{"nctId":"NCT00913120","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":610}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"recentPublications":[{"date":"2026 Feb 19","pmid":"41714948","title":"Trough anticoagulant levels of high-dose versus standard-dose intravenous enoxaparin in patients undergoing trans-radial coronary angiography alone.","journal":"BMC cardiovascular disorders"},{"date":"2024 Jan","pmid":"37794281","title":"Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials.","journal":"Internal and emergency medicine"},{"date":"2022 Jul 9","pmid":"35253872","title":"Apixaban in a porcine model of mechanical valve thrombosis in pulmonary position-a pilot study.","journal":"Interactive cardiovascular and thoracic surgery"},{"date":"2016 Mar-Apr","pmid":"27050402","title":"Retrospective analysis of 3 different antithrombotic prophylaxis regimens in bariatric surgery.","journal":"Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery"},{"date":"2013 Sep","pmid":"24025294","title":"NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta.","journal":"Annals of the Royal College of Surgeons of England"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clexane"],"phase":"marketed","status":"active","brandName":"Enoxaparin (High-dose Group)","genericName":"Enoxaparin (High-dose Group)","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), Deep vein thrombosis and pulmonary embolism prophylaxis and treatment, Acute ST-elevation myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}